anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A regimen for the treatment of analgesia which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: about 10-50 mg of tramadol on days 1-3; about 20-100 mg of tramadol on days 4-6; about 30-150 mg of tramadol on days 7-9; and about 40-400 mg of tramadol on days 10-28 and thereafter. 2. A regimen for the treatment of analgesia according to claim 1 which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: about 10-50 mg of tramadol on days 1-3; about 20-100 mg of tramadol on days 4-6; about 30-150 mg of tramadol on days 7-9; and about 40-200 mg of tramadol on days 10-28 and thereafter. 3. A regimen for the treatment of analgesia according to claim 1 which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: 25 mg of tramadol on days 1-3; 50 mg of tramadol on days 4-6; 75 mg of tramadol on days 7-9; 100 mg of tramadol on days 10-12; 150 mg of tramadol on days 13-15; and 200 mg of tramadol on days 16-28 and thereafter. 4. A regimen for the treatment of analgesia according to claim 1 which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: 50 mg of tramadol on days 1-3; 100 mg of tramadol on days 4-6; 150 mg of tramadol on days 7-9; and 200 mg of tramadol on day 10 and thereafter. 5. A regimen for the treatment of analgesia according to claim 1 which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: 25 mg of tramadol on days 1-3; 50 mg of tramadol on days 4-6; 75 mg of tramadol on days 7-9; 100 mg of tramadol on days 10-12; 150 mg of tramadol on days 13-15; and 200 mg of tramadol on day 16 and thereafter. 6. A regimen for the treatment of analgesia according to claim 1 which comprises administering a pharmaceutical composition containing tramadol as the active ingredient which comprises: 25 mg of tramadol q. d. on days 1-3, 25 of mg of tramadol b. i. d. on days 4-6, 25 mg of tramadol t. i. d. on days 7-9, 25 mg of tramadol q. i. d. on days 10-12, and 50 mg of tramadol t. i. d. on days 13-28. 7. The method of claim 1 wherein tramadol is administered in the form of tramadol hydrochloride.
The detection of psychosis and its prodrome have unique considerations in a child and adolescent population. Young people attending CAMHS are already a high-risk group, which confers significant limitations in applying the current clinical high-risk (CHR) model. This has catalysed calls for a transdiagnostic approach to psychosis risk prediction, but without a clear pathway forward. We contribute to the debate opened by Salazar de Pablo and Arango (2023, Child and Adolescent Mental Health) on the role of CAMHS in this initiative. CAMHS have a key role in developing comprehensive longitudinal datasets to inform risk models. Closer integration with early intervention in psychosis (EIP) services will be needed to realise this potential. This integration is also required to reliably detect prodromes and emerging psychosis in young people. Where there is robust evidence to support prevention initiatives, we should proceed with their implementation, even in the absence of enhanced risk models.
1420449 Medicinal iron preparations DEUTSCHE GOLD-UND SILBER-SCHEIDEANSTALT 31 July 1973 [31 July 1972] 36460/73 Heading ASB [Also in Division C3] Agents for the peroral treatment of acute anaemia and/or for the prophylactic treatment of anaemia in warm-blooded omnivores, e.g. piglets, comprise iron salts or complexes of polymers having an average degree of polymerisation of 3-600 and defined in terms of the molar percentages of 5 different types of unit, including essentially units containing carboxyl groups together with units containing aldehyde groups and/or units containing hydroxy groups. Units derived from dicarboxylic acids and units obtained by ring- opening polymerisation of aldehydes are optional. Suitable polymers are (a) a copolymer containing aldehyde groups and carboxyl groups and prepared by oxidising copolymerisation of acrylic acid and acrolein, and (b) a copolymer containing hydroxy and carboxyl groups prepared by subjecting polymer (a) to a Cannizzaro reaction with NaOH. In Example 1, an iron salt/complex of a (b)-type polymer is used per se in the treatment of piglets. The polymers may be used in admixture with other pharmaceutically active substances e.g. vitamins and antibiotics, excipients or other additives, e.g. antioxidants.
The present invention relates to a Chinese medicine composition which contains plant raw materials and inorganic effective ingredients. The Chinese medicine composition of the present invention contains dried alum, natural indigo, coptis, Chinese gall, catechu and sodium thiosulfate. The medicines are pulverized into fine powder, and the fine powder is uniformly mixed to prepare the toxin-absorbing and drying medicine. The Chinese medicine composition has the efficacy of killing bacteria, relieving inflammation, eliminating swelling, discharging pus, drying affected parts and generating scabs. The Chinese medicine composition has good therapeutic effect on suppurative cutaneous infection, bullous pustulosis, pustule sores, scalds, burns, bedsores, hemorrhoids, etc. The Chinese medicine composition has the advantages of easy preparation, low cost and easy patient acceptance.
Cosmetic use of an active ingredient (I) from Lens culinarisor Lens esculentain a cosmetic composition to prevent or mitigate the unsightly aspect of dilated pores on the skin, is claimed. Independent claims are included for: (1) (I) obtained from Lens culinarisor Lens esculenta, having carbohydrate content of >= 16%; (2) a preparation of (I) comprising at least one step of solubilization of grains of Lens culinarisor Lens esculentain aqueous medium and at least one enzymatic hydrolysis; (3) a cosmetic composition for topical application on the skin to mitigate the unsightly aspect of dilated pores, comprising 0.1-20 wt.% of (I) having carbohydrate (16-50%); (4) a cosmetic process for caring of the human skin, to mitigate the unsightly large pores, reduce shine and refine the skin texture, comprising topical application of a composition containing (I) derived from Lens culinarison the skin. ACTIVITY : Dermatological. MECHANISM OF ACTION : Transglutaminase-1 expression stimulator; Involucrin expression stimulator; Collagen I expression stimulator. The ability of (I) (from Lens culinaris(0.5%)) to stimulate collagen I expression was tested in normal human fibroblast by measuring the expression of mRNA. The result showed that the percentage of mRNA was 200.
We systematically investigated proteasome-mediated generation of fourteen different well-defined CTL epitopes. Synthetic peptides (26 residues) containing known CTL-epitopes flanked by their natural amino acids have been used as substrates for the 20S proteasome in vitro. After several time intervals, peptide digests were analyzed by electrospray mass spectrometry to determine the major fragments produced by the proteasome. In 12 out of 14 peptide digests, the correct C-terminal residue of the CTL-epitope was generated by proteasomal cleavage. The N-terminal residue of the epitope was generally not exactly defined by the proteasome. In most cases, fragments with the correct C-terminal residue were elongated several amino acids at the N-terminus. For two CTL-epitopes we found that their longer precursor peptides, as generated by the proteasome, correlated with efficient TAP translocation. For one CTL-epitope we found that a natural mutation directly flanking the C-terminal residue of the CTL-epitope precursor disrupted the specific C-terminal cleavage site and resulted in a non-functional cleavage product. This study indicates that proper CTL-epitope generation requires correct C-terminal cleavage by the proteasome, and allows N-terminal elongation of CTL-epitope precursor peptides.
BACKGROUND: The process underlying Fontan pathophysiology is multifactorial and may include gut dysbiosis (GD). We investigated the presence of GD and elucidated its correlation with Fontan pathophysiology.
METHODS AND RESULTS: Gut microbiomes of 155 consecutive patients with Fontan pathophysiology and 44 healthy individuals were analyzed using 16S rRNA sequencing of bacterial DNA extracted from fecal samples. GD was evaluated on the basis of α and ß diversities of the gut microbiome and was compared with natural log-transformed C-reactive protein, hemodynamics, von Willebrand factor antigen (a bacterial translocation marker), Mac-2 binding protein glycosylation isomer (a liver fibrosis indicator), peak oxygen uptake, and heart failure hospitalization. Patients with Fontan exhibited GD in terms of α and ß diversities as compared with controls (P<0.01). Reduced α diversity was associated with a failed hemodynamic phenotype, hypoxia, high natural log-transformed C-reactive protein levels, and elevated von Willebrand factor antigen and Mac-2 binding protein glycosylation isomer levels (P<0.05-0.01). In addition to elevated von Willebrand factor antigen and hypoxia, decreased α diversity was independently correlated with a high natural log-transformed C-reactive protein level (P<0.05), which was associated with liver imaging abnormalities and a heightened risk of heart failure hospitalization (P<0.01 for both).
CONCLUSIONS: Patients with Fontan pathophysiology exhibited GD compared with healthy individuals, and GD was linked to failed hemodynamics and systemic inflammation with a poor prognosis. Therefore, GD may play a pivotal role in a failing Fontan status, including Fontan-associated liver disease, through GD-associated systemic inflammation.
<P>PROBLEM TO BE SOLVED: To enable cure of ligament injury, osteoporosis and healing of wound, and to perform tissue engineering, medicine delivery, and prevention of tumor cell metastasis.  <P>SOLUTION: A method executed is: preparing a ground substance/cell combination to repair injured musculoskeletal tissue of a patient. The ground substance/cell combination is to be transplanted to the position of injured musculoskeletal tissue. The method comprises a step to breed a musculoskeletal cell or a marrow interstitium stem cell taken from a patient on the ground substance. The step is executed by bringing the cell into contact with a medicine in sufficient concentration to obstruct or promote the in vitro generation of alpha smooth muscle actin (SMA) or biological activity.  <P>COPYRIGHT: (C)2004,JPO
The invention discloses an alkaloid compound as well as a preparation method and an application of the alkaloid compound. The alkaloid compound has a molecular formula of C15H21NO4. The preparation method of the alkaloid compound comprises the steps that activated Pestalotiopsis sp. fungi Z233 are inoculated into culture liquid, and the fermentation culture is carried out for 10 to 40 days at 20 to 30 DEG C; mycelia and fermentation liquid are obtained through separation after the fermentation culture; after the mycelia are leached, extracted and concentrated by organic solvents, mycelium extractives are obtained; or the fermentation liquid is extracted and concentrated to obtain fermentation liquid extractives; and the chromatographic separation and the purification treatment are carried out on the mycelium extractives or the fermentation liquid extractives, and the alkaloid compound is prepared. The alkaloid compound with a novel structure is extracted and separated from fermentation culture substances of Sargassum horneri epiphytic Pestalotiopsis sp. fungi Z233, and the alkaloid compound has better antitumor activity, can be used for preparing antitumor medicine and tumor prevention health-care food and has good development prospects.
Patients with chronic pain often develop comorbid depressive symptoms, which makes the pain symptoms more complicated and refractory. However, the underlying mechanisms are poorly known. Here, in a repeated complete Freund's adjuvant (CFA) male mouse model, we reported a specific regulatory role of the paraventricular thalamic nucleus (PVT) glutamatergic neurons, particularly the anterior PVT (PVA) neurons, in mediating chronic pain and depression comorbidity (CDC). Our c-Fos protein staining observed increased PVA neuronal activity in CFA-CDC mice. In wild-type mice, chemogenetic activation of PVA glutamatergic neurons was sufficient to decrease the 50% paw withdrawal thresholds (50% PWTs), while depressive-like behaviors evaluated with immobile time in tail suspension test (TST) and forced swim test (FST) could only be achieved by repeated chemogenetic activation. Chemogenetic inhibition of PVA glutamatergic neurons reversed the decreased 50% PWTs in CFA mice without depressive-like symptoms and the increased TST and FST immobility in CFA-CDC mice. Surprisingly, in CFA-CDC mice, chemogenetically inhibiting PVA glutamatergic neurons failed to reverse the decrease of 50% PWTs, which could be restored by rapid-onset antidepressant S-ketamine. Further behavioral tests in chronic restraint stress mice and CFA pain mice indicated that PVA glutamatergic neuron inhibition and S-ketamine independently alleviate sensory and affective pain. Molecular profiling and pharmacological studies revealed the 5-hydroxytryptamine receptor 1D (Htr1d) in CFA pain-related PVT engram neurons as a potential target for treating CDC. These findings identified novel CDC neuronal and molecular mechanisms in the PVT and provided insight into the complicated pain neuropathology under a comorbid state with depression and related drug development.
PURPOSE: A composition containing wheatgrass extract for preventing and treating diabetes is provided to ensure anti-diabetic possibility. CONSTITUTION: A health food for preventing and treating diabetes contains wheatgrass extract as an active ingredient. The health food is powder, granules, tablets, capsules, or drink. The health food contains beta-glucan or gamma-amino butyric acid(GABA). A pharmaceutical composition for preventing and treating diabetes contains the wheatgrass extract as an active ingredient. The wheatgrass extract is prepared by freeze-drying, adding purified water to wheatgrass powder, and extracting at 2-5°C for 12-36 hours.
Countless therapeutic antibodies are currently available for the treatment of a broad range of diseases. Some target molecules of therapeutic antibodies are involved in the pathogenesis of sensorineural hearing loss (SNHL), suggesting that SNHL may be a novel target for monoclonal antibody (mAb) therapy. When considering mAb therapy for SNHL, understanding of the pharmacokinetics of mAbs after local application into the middle ear is crucial. To reveal the fundamental characteristics of mAb pharmacokinetics following local application into the middle ear of guinea pigs, we performed pharmacokinetic analyses of mouse monoclonal antibodies to FLAG-tag (FLAG-mAbs), which have no specific binding sites in the middle and inner ear. FLAG-mAbs were rapidly transferred from the middle ear to the cochlear fluid, indicating high permeability of the round window membrane to mAbs. FLAG-mAbs were eliminated from the cochlear fluid 3 h after application, similar to small molecules. Whole-body autoradiography and quantitative assessments of cerebrospinal fluid and serum demonstrated that the biodistribution of FLAG-mAbs was limited to the middle and inner ear. Altogether, the pharmacokinetics of mAbs are similar to those of small molecules when locally applied into the middle ear, suggesting the necessity of drug delivery systems for appropriate mAb delivery to the cochlear fluid after local application into the middle ear.
This study aims to evaluate the oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting patients with a new coronavirus disease. The aim of the study is to determine the preventive role of this drug in the framework of reducing the incidence of coronavirus infection in risk groups (medical personnel). Several studies show, that the acute respiratory syndrome coronavirus SARS-CoV uses endosomal cysteine proteases cathepsin B and L (CatB/L) and the transmembrane protease serine type 2 (TMPRSS2) for the priming of the viral S-protein. The new coronavirus SARS-CoV-2 penetrates into alveolar epithelial type two cells through a similar mechanism. In detail, viral S-protein binds to pneumocyte angiotensin-converting enzyme 2 (ACE2) and then undergoes cleaving by TMPRSS2 in S1- and S2-subunits. This leads to the release of a fusion peptide, which allows the virus to enter the cell via endocytosis. Therefore, the protease TMPRSS2 can serve as a target for pharmacological agents to prevent the penetration of the SARS-CoV-2 into the cell. Bromhexine blocks the TMPRSS2 ability to activate a zymogen precursor of tissue plasminogen activator in vitro. Interestingly, TMPRSS2 is blocked by much lower concentrations then required to inactivate other proteases in the cell culture. However, these data cannot be simply extended to the clinical practice: whether the concentration of bromhexine in the lung tissue of properly treated patients would be enough to prevent the virus entry through the TMPRSS2-inactivation remains unclear. A randomized study in people at risk for coronavirus infection will clarify the role of Bromhexine hydrochloride as a prevention of this disease.
Objective: To evaluate the efficacy and safety of CD30 antibody-drug conjugates (ADC) brentuximab vedotin (BV) combined with chemotherapy in children with refractory or relapsed classic Hodgkin's lymphoma (R/R cHL). Methods: Clinical data (including age, gender, B symptoms, clinical stage, previous treatment, etc.) of the 10 R/R cHL children diagnosed and treated at Beijing Children's Hospital Affiliated to Capital Medical University from October 2021 to August 2023 were analyzed retrospectively. According to the different intensity of chemotherapy drugs, the dose of BV applied in the same course of treatment was 1.8 mg/kg for BV applied once every 3 weeks, and 1.2 mg/kg for BV applied once every 2 weeks. All 10 patients received at least 2 cycles of BV combined with chemotherapy and were evaluated every 2 cycles. The patients were followed up until May 31, 2024. The infusion reactions and adverse reactions after treatment were recorded. Results: In all 10 patients, there were 7 males and 3 females, the age ranged from 5.3-16.9 years, and there were 6 cases of refractory and 4 cases of relapsed. There were 6 cases of nodular sclerosis type, 2 cases of mixed cell type, 1 case of lymphocyte-rich type, and 1 case of lymphodepletion type. There were 5 cases of stage Ⅳ and 5 cases of stage Ⅲ. Previous treatment was mainly chemotherapy, 4 cases received radiotherapy and 1 case received programmed cell death protein 1 (PD-1) antibody therapy. The follow-up time ranged from 9 to 27 months. A total of 43 courses with 49 doses of BV alone or combined with chemotherapy were recorded, and the number of courses was 2 to 10 times. All 10 children responded to the treatment, and 9 achieved complete remission. BV infusion was successfully completed in all cases. A total of 28 cases of grade 3 or above adverse events were recorded, mainly myelosuppression, all of which were related to chemotherapy and did not affect sequential treatment. Conclusion: Brentuximab vedotin has demonstrated efficacy and a tolerable safety profile in the treatment of refractory and relapsed CD30-positive Hodgkin's lymphoma in children.
A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump. The blood component separation device separates the drawn blood into a first blood component and a second blood component, and sends the first blood component to a first blood component bag. The first return line fluidly connects the venous-access device and the blood component separation device. The recirculation line connects the first blood component container and the separation device. The second return line fluidly connects the first blood component container and the first return line and is configured to return the first blood component within the first blood container to the subject.
BACKGROUND: Stem cell therapy for the treatment of osteonecrosis of the femoral head (ONFH) showed promising outcomes. However, ONFH with a large lesion in the weight-bearing portion is a poor prognostic factor and still challenging issue to be solved. We aimed to evaluate the effect of tissue-engineered bone regeneration for this challenging condition to preserve the femoral head.
METHODS: A total of 7 patients (9 hips) with ONFH who received osteoblasts expanded ex vivo from bone marrow-derived mesenchymal stem cells (BMdMSCs) and calcium metaphosphate (CMP) as scaffolds from March 2002 to March 2004 were retrospectively reviewed. The median age was 27.0 years (interquartile range [IQR], 23.0-34.0 years), and the median follow-up period was 20.0 years (IQR, 11.0-20.0 years). After culture and expansion of stem cells, we performed core decompression with BMdMSC implantation at a median number of 10.1 ×107 (IQR, 9.9-10.9 ×107). To evaluate radiographic outcomes, the Association Research Circulation Osseous (ARCO) classifications, the Japanese Investigation Committee (JIC) classification, and modified Kerboul combined necrotic angle (mKCNA) were evaluated preoperatively and during follow-up. Clinical outcomes were evaluated by a visual analog scale (VAS) and Harris Hip Score (HHS).
RESULTS: The preoperative stage of ONFH was ARCO 2 in 5 hips and ARCO 3a in 4 hips. The ARCO staging was maintained in 3 hips of ARCO 2 and 4 hips of ARCO 3a. Two hips of ARCO 2 with radiographic progression underwent total hip arthroplasty. According to mKCNA, 2 hips showed medium lesions, and 7 hips showed large lesions. The size of necrotic lesion was decreased in 4 hips (2 were ARCO 2 and 2 were ARCO 3a). There were no significant changes in JIC classification in all hips (type C1: 3 hips and type C2: 6 hips) (p = 0.655). Clinically, there were no significant changes in the VAS and HHS between preoperative and last follow-up (p = 0.072 and p = 0.635, respectively).
CONCLUSIONS: Tissue engineering technique using osteoblasts expanded ex vivo from BMdMSC and CMP showed promising outcomes for the treatment of pre-collapsed and early-collapsed stage ONFH with medium-to-large size, mainly located in weight-bearing areas.
A method for delivering medical samples with a laboratory request from an extraction point to a laboratory is presented. The availability of the test to be performed on a sample during a time at a first laboratory is checked. If the test cannot be performed during that time, laboratory attributes available at laboratories are checked via laboratory broker devices. A suitable candidate laboratory can be identified amongst the laboratories based on the laboratory attributes of the suitable candidate laboratory. The identified suitable candidate laboratory and the first laboratory communicate with each other regarding the feasibility of the suitable candidate laboratory to perform the test on the sample. If feasible to perform the test at the suitable candidate laboratory, the sample and the laboratory request are delivered to the suitable candidate laboratory for testing. After test performance at the suitable candidate laboratory, the test results are communicated to the extraction point.